![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 27, 28283-28291, July 2, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



From the
Departments of
Medicine and ¶Clinical Biochemistry, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/Medical Research Council Building, Hills Road, Cambridge CB2 2XY, United Kingdom
The dementia familial encephalopathy with neuroserpin inclusion bodies (FENIB) is caused by the accumulation of mutant neuroserpin within neurons (Davis, R. L., Shrimpton, A. E., Holohan, P. D., Bradshaw, C., Feiglin, D., Sonderegger, P., Kinter, J., Becker, L. M., Lacbawan, F., Krasnewich, D., Muenke, M., Lawrence, D. A., Yerby, M. S., Shaw, C.-M., Gooptu, B., Elliott, P. R., Finch, J. T., Carrell, R. W., and Lomas, D. A. (1999) Nature 401, 376379), but little is known about the trafficking of wild type and mutant neuroserpins. We have established a cell model to study the processing of wild type neuroserpin and the Syracuse (S49P) and Portland (S52R) mutants that cause FENIB. Here we show that Syracuse and Portland neuroserpin are retained soon after their synthesis in the endoplasmic reticulum and that the limiting step in their processing is the transport to the Golgi complex. This is in contrast to the wild type protein, which is secreted into the culture medium. Mutant neuroserpin is retained within the endoplasmic reticulum as polymers, similar to those isolated from the intraneuronal inclusions in the brains of individuals with FENIB. Remarkably, the Portland mutant showed faster accumulation and slower secretion compared with the Syracuse mutant, in keeping with the more severe clinical phenotype found in patients with the Portland variant of neuroserpin. Both mutant and wild type neuroserpin were partially degraded by proteasomes. Taken together, our results provide further understanding of how cells handle defective but ordered mutant proteins and provide strong support for a common mechanism of disease caused by mutants of the serine protease inhibitor superfamily.
Received for publication, December 3, 2003 , and in revised form, April 16, 2004.
* This work was supported by the Medical Research Council (UK), the Wellcome Trust, and Papworth National Health Service Trust. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|| A Wellcome Trust Senior Fellow.
To whom correspondence should be addressed. Tel.: 44-1223-336825; Fax: 44-1223-336827; E-mail: em285{at}cam.ac.uk.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
E. Miranda, I. MacLeod, M. J. Davies, J. Perez, K. Romisch, D. C. Crowther, and D. A. Lomas The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB Hum. Mol. Genet., June 1, 2008; 17(11): 1527 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Granell, G. Baldini, S. Mohammad, V. Nicolin, P. Narducci, B. Storrie, and G. Baldini Sequestration of Mutated {alpha}1-Antitrypsin into Inclusion Bodies Is a Cell-protective Mechanism to Maintain Endoplasmic Reticulum Function Mol. Biol. Cell, February 1, 2008; 19(2): 572 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Nielsen, L. Minthon, E. Londos, K. Blennow, E. Miranda, J. Perez, D. C. Crowther, D. A. Lomas, and S. M. Janciauskiene Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies Neurology, October 16, 2007; 69(16): 1569 - 1579. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Galliciotti, M. Glatzel, J. Kinter, S. V. Kozlov, P. Cinelli, T. Rulicke, and P. Sonderegger Accumulation of Mutant Neuroserpin Precedes Development of Clinical Symptoms in Familial Encephalopathy with Neuroserpin Inclusion Bodies Am. J. Pathol., April 1, 2007; 170(4): 1305 - 1313. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Kinghorn, D. C. Crowther, L. K. Sharp, C. Nerelius, R. L. Davis, H. T. Chang, C. Green, D. C. Gubb, J. Johansson, and D. A. Lomas Neuroserpin Binds Abeta and Is a Neuroprotective Component of Amyloid Plaques in Alzheimer Disease J. Biol. Chem., September 29, 2006; 281(39): 29268 - 29277. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. de Groot and G. J. M. Martens Expression of Neuroserpin Is Linked to Neuroendocrine Cell Activation Endocrinology, September 1, 2005; 146(9): 3791 - 3799. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thomas, Z. Yu, N. Dadgar, S. Varambally, J. Yu, A. M. Chinnaiyan, and A. P. Lieberman The Unfolded Protein Response Modulates Toxicity of the Expanded Glutamine Androgen Receptor J. Biol. Chem., June 3, 2005; 280(22): 21264 - 21271. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Onda, D. Belorgey, L. K. Sharp, and D. A. Lomas Latent S49P Neuroserpin Forms Polymers in the Dementia Familial Encephalopathy with Neuroserpin Inclusion Bodies J. Biol. Chem., April 8, 2005; 280(14): 13735 - 13741. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |